Magnetar Financial LLC Sells 111,853 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Magnetar Financial LLC significantly reduced its stake in Thermo Fisher Scientific Inc. by 88.8%, owning 14,084 shares valued at approximately $7.01 million after selling 111,853 shares in the first quarter.
• CEO Marc N. Casper sold 10,000 shares at an average price of $500.96, leading to a 7.99% decrease in his holdings, while insider sales totaled nearly $13.6 million over the past 90 days.
• Thermo Fisher Scientific's latest earnings report revealed $10.86 billion in revenue, exceeding estimates, and it announced a $0.43 quarterly dividend, reflecting a 0.4% yield with a payout ratio of 9.95%.

Magnetar Financial LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 88.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,084 shares of the medical research company's stock after selling 111,853 shares during the quarter. Magnetar Financial LLC's holdings in Thermo Fisher Scientific were worth $7,008,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of TMO. Bernard Wealth Management Corp. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $25,000. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific during the fourth quarter worth $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific during the first quarter worth $31,000. IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific during the first quarter worth $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in Thermo Fisher Scientific during the first quarter worth $37,000. Institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on TMO shares. William Blair started coverage on shares of Thermo Fisher Scientific in a report on Monday, August 18th. They issued an "outperform" rating on the stock. Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. HSBC restated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,896 shares of company stock valued at $13,603,438. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

TMO stock traded up $3.31 during mid-day trading on Monday, hitting $493.05. 1,228,194 shares of the company were exchanged, compared to its average volume of 1,834,312. The business has a 50 day simple moving average of $452.50 and a 200-day simple moving average of $453.78. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $186.18 billion, a PE ratio of 28.52, a price-to-earnings-growth ratio of 2.63 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period last year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is presently 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.